CorePharma Launches Methylphenidate Hydrochloride Tablets USP

MIDDLESEX, N.J., May 8, 2014 /PRNewswire/ -- CorePharma, LLC ("CorePharma"), a developer, manufacturer, and marketer of targeted generic prescription pharmaceuticals, announced today that it has launched Methylphenidate Hydrochloride Tablets USP ("Methylphenidate"), the generic version of Novartis' Ritalin®. Methylphenidate is indicated for the treatment of narcolepsy and attention deficit disorders.  CorePharma received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) on March 12, 2014. The product is available in the 5, 10, and 20mg strengths and has begun shipping.

The methylphenidate immediate release tablet market had U.S. sales of approximately $243 million according to IMS data as of December 2013.

About CorePharma
CorePharma, Middlesex, NJ, is a developer, manufacturer and marketer of targeted generic prescription pharmaceuticals across a variety of dosage forms and therapeutic categories. CorePharma operates a state-of-the-art facility, totaling 112,000 square feet of space, in Middlesex, NJ.  The company actively seeks partnerships, licensing and acquisition opportunities to complement and expand its product portfolio. CorePharma is a wholly owned subsidiary of Tower Holdings, Inc.  RoundTable Healthcare Partners, an operating-oriented private equity firm focused exclusively on the healthcare industry, owns a majority share of Tower Holdings.

SOURCE CorePharma, LLC